Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms.

Published on Apr 17, 2021in Journal of Clinical Medicine3.303
· DOI :10.3390/JCM10081741
Giovanni Centonze11
Estimated H-index: 11
Vincenzo Lagano1
Estimated H-index: 1
+ 16 AuthorsMassimo Milione31
Estimated H-index: 31
High-grade Gastroenteropancreatic Neuroendocrine neoplasms (H-NENs) comprehend well-differentiated tumors (NET G3) and poorly differentiated carcinomas (NEC) with proliferative activity indexes as mitotic count (MC) >20 mitoses/10 HPF and Ki-67 >20%. At present, no specific therapy for H-NENs exists and the several evidences of microenvironment involvement in their pathogenesis pave the way for tailored therapies. Forty-five consecutive cases, with available information about T-cell, immune, and non-immune markers, from surgical pathology and clinical databases of 2 Italian institutions were immunostained for Arginase, CD33, CD163 and CD66 myeloid markers. The association between features was assessed by Spearman’s correlation coefficient. A unsupervised K-means algorithm was used to identify clusters of patients according to inputs of microenvironment features and the relationship between clusters and clinicopathological features, including cancer-specific survival (CSS), was analyzed. The H-NEN population was composed of 6 (13.3%) NET G3 and 39 (86.7%) NEC. Overall, significant positive associations were found between myeloid (CD33, CD163 and Arginase) and T/immune markers (CD3, CD4, CD8, PD-1 and HLA-I). Myeloid and T-cell markers CD3 and CD8 identified two clusters of patients from unsupervised K-means analysis. Cases grouped in cluster 1 with more myeloid infiltrates, T cell, HLA and expression of inhibitory receptors and ligands in the stroma (PD-1, PD-L1) had significantly better CSS than patients in cluster 2. Multivariable analysis showed that Ki-67 (>55 vs. <55, HR 8.60, CI 95% 2.61–28.33, p < 0.0001) and cluster (1 vs. 2, HR 0.43, CI 95% 0.20–0.93, p = 0.03) were significantly associated with survival. High grade gastroenteropancreatic neuroendocrine neoplasms can be further classified into two prognostic sub-populations of tumors driven by different tumor microenvironments and immune features able to generate the framework for evaluating new therapeutic strategies.
#1Alex John Liu (Mayo Clinic)H-Index: 2
#2Benjamin Edward Ueberroth (Mayo Clinic)H-Index: 1
Last. Mohamad Bassam Sonbol (Mayo Clinic)H-Index: 16
view all 9 authors...
INTRODUCTION Recent classification of neuroendocrine neoplasms has defined well-differentiated high-grade neuroendocrine tumors (NET G3) as a distinct entity from poorly differentiated neuroendocrine carcinoma (NEC). The optimal treatment for NET G3 has not been well-described. This study aims to evaluate metastatic NET G3 response to different treatment regimens. MATERIALS AND METHODS This is a retrospective study of NET G3 patients within the Mayo Clinic database. Patients' demographics along ...
5 CitationsSource
#2Yixuan Zhang (SYSU: Sun Yat-sen University)H-Index: 3
#3Luohai Chen (SYSU: Sun Yat-sen University)H-Index: 6
Last. Jie Chen (SYSU: Sun Yat-sen University)H-Index: 31
view all 8 authors...
Background Expanded myeloid-derived suppressor cells (MDSCs) correlate with disseminated metastases and poor prognosis in various human cancers. However, the role of MDSCs in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) is still unknown. We investigated the distribution of MDSCs and their clinical significance in patients with GEP-NENs. Methods Peripheral blood mononuclear cells (PBMCs) and paraffin-embedded tumor tissues were acquired from patients with GEP-NENs. Multicolor flow c...
1 CitationsSource
#1Abir Salwa AliH-Index: 5
#2Seppo W. LangerH-Index: 25
Last. Eva Tiensuu JansonH-Index: 49
view all 16 authors...
Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinic...
3 CitationsSource
#1Barbara Kiesewetter (Medical University of Vienna)H-Index: 17
#2Markus Raderer (Medical University of Vienna)H-Index: 79
Neuroendocrine tumours (NETs) constitute a heterogeneous group of neoplasms characterised by variable endocrine activity and somatostatin receptor expression, with the latter allowing the use of targeted therapeutic concepts. Currently accepted treatment strategies for advanced well-differentiated NET include somatostatin analogues octreotide and lanreotide, peptide receptor radionuclide therapy using radiolabelled somatostatin analogues, mammalian target of Rapamycin inhibitor everolimus, tyros...
7 CitationsSource
#1Massimo MilioneH-Index: 31
#2Mattia BoeriH-Index: 21
Last. Ugo PastorinoH-Index: 70
view all 16 authors...
Almost 25% of lung cancers (LCs) occur in never-smokers. LC inflammatory profile, based on plasma C-reactive protein levels (CRP), predicts mortality, independently by smoking-status. We hypothesized that: CRP could be associated with tumor immune contexture (TIC) in never-smokers and both these two parameters may improve their prognosis. Sixty-eight never-smokers LC patients with high or low CRP were selected. The programmed cell death protein 1 (PD-1) and its ligand (PD-L1), the human leukocyt...
1 CitationsSource
#1Anna PellatH-Index: 6
#2Romain Coriat (University of Paris)H-Index: 19
The 2017 World Health Organization (WHO) classification of neuroendocrine neoplasms (NEN) of the digestive tract introduced a new category of tumors named well-differentiated grade 3 neuroendocrine tumors (NET G−3). These lesions show a number of mitosis, or a Ki−67 index higher than 20% with a well-differentiated morphology, therefore separating them from neuroendocrine carcinomas (NEC) which are poorly differentiated. It has become clear that NET G−3 show differences not only in morphology but...
12 CitationsSource
#1Ilaria Maggio (UNIBO: University of Bologna)H-Index: 6
#2Lisa Manuzzi (UNIBO: University of Bologna)H-Index: 6
Last. Davide Campana (UNIBO: University of Bologna)H-Index: 28
view all 6 authors...
Background: Neuroendocrine neoplasms are rare entities consisting of a heterogeneous group of tumors that can originate from neuroendocrine cells present in the whole body. Their different behavior, metastatic potential, and prognosis are highly variable, depending on site of origin, grade of differentiation, and proliferative index. The aim of our work is to summarize the current knowledge of immunotherapy in different neuroendocrine neoplasms and its implication in clinical practice. Results: ...
15 CitationsSource
#1Ting-Fang He (City of Hope National Medical Center)H-Index: 10
#2Susan E. Yost (City of Hope National Medical Center)H-Index: 13
Last. Yuan Yuan (City of Hope National Medical Center)H-Index: 32
view all 13 authors...
The evolutionary changes in immune profiles of triple negative breast cancer (TNBC) are not well understood, although it is known that immune checkpoint inhibitors have diminished activity in heavily pre-treated TNBC patients. This study was designed to characterize immune profile changes of longitudinal tumor specimens by studying immune subsets of tumor infiltrating lymphocytes (TILs) in paired primary and metastatic TNBC in a cohort of "poor outcome" (relapsed within 5 years) patients. Immune...
13 CitationsSource
#1Iris D. Nagtegaal (IARC: International Agency for Research on Cancer)H-Index: 85
#2Robert D Odze (IARC: International Agency for Research on Cancer)H-Index: 1
Last. Ian A. Cree (IARC: International Agency for Research on Cancer)H-Index: 59
view all 9 authors...
The WHO classification of digestive system tumours presented in the first volume of the WHO classification of tumours series, 5th edition, reflects important advancements in our understanding of tumours of the digestive system (Table ​(Table1).1). For the first time, certain tumour types are defined as much by their molecular phenotype as their histological characteristics; however, in most instances histopathological classification remains the gold standard for diagnosis. The WHO classification...
464 CitationsSource
#1Wu-Hu ZhangH-Index: 5
#2Wen-Quan WangH-Index: 15
Last. Liang LiuH-Index: 26
view all 5 authors...
Abstract Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a group of rare tumors that are increasing in prevalence. The complex tumor immune microenvironment (TIME) plays an important role in tumor development and the response to immunotherapy but is poorly understood. In this review, the components of the TIME are described in detail, including discussion about infiltrating immune cells, the immune checkpoint system, the cytokine and chemokine milieu, and immunomodulatory factors....
12 CitationsSource
Cited By2
#1Katharina Detjen (Charité)H-Index: 20
#2Raik Otto (Humboldt University of Berlin)H-Index: 4
Last. T Lüdde (HHU: University of Düsseldorf)
view all 16 authors...
BACKGROUND The clinical management of high-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is challenging due to disease heterogeneity, illustrating the need for reliable biomarkers facilitating patient stratification and guiding treatment decisions. FMS-like tyrosine kinase 3 ligand (Flt3L) is emerging as a prognostic or predictive surrogate marker of host tumoral immune response and might enable the stratification of patients with otherwise comparable tumor features. METHODS We...
#1Shengnan Zhou (Peking Union Medical College Hospital)
#2Shitao Jiang (Peking Union Medical College Hospital)
Last. Xiao-Dong He (Peking Union Medical College Hospital)H-Index: 11
view all 8 authors...
Background: For this study, we explored the prognostic profiles of biliary neuroendocrine neoplasms (NENs) patients and identified factors related to prognosis. Further, we developed and validated an effective nomogram to predict the overall survival (OS) of individual patients with biliary NENs. Methods: We included a total of 446 biliary NENs patients from the SEER database. We used Kaplan-Meier curves to determine survival time. We employed univariate and multivariate Cox analyses to estimate...